Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333146 | 0.92 | ALDH1A1 (0.59) | ALDH1A1MAPTKDM4EGAAKMT2A | |
| SCHEMBL4332978 | 0.91 | ALDH1A1 (0.58) | ALDH1A1MAPTKDM4EGAAKMT2A | |
| SCHEMBL4332975 | 0.91 | ALDH1A1 (0.58) | ALDH1A1MAPTKDM4EGAAKMT2A | |
| SCHEMBL3502865 | 0.85 | MEN1 (0.58) | ALDH1A1GAAKMT2AMEN1MAPK1 | |
| SCHEMBL680836 | 0.84 | TSHR (0.69) | ALDH1A1MAPTKDM4EGAAKMT2A | |
| SCHEMBL1753925 | 0.84 | GAA (0.70) | ALDH1A1KDM4EGAAKMT2AMEN1 | |
| SCHEMBL10016247 | 0.83 | MEN1 (0.55) | ALDH1A1MAPTGAAKMT2AMEN1 | |
| SCHEMBL13841452 | 0.83 | POLB (0.74) | ALDH1A1KMT2AMEN1HTTHPGD | |
| SCHEMBL5206026 | 0.81 | HPGD (0.75) | ALDH1A1MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6663354 | 0.81 | MEN1 (0.53) | ALDH1A1MAPTGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4034532-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE | Exelixis, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114787144-A | Pyridone compounds and methods for modulating protein kinases | 埃克塞里艾克西斯公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021062245-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE | EXELIXIS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| CN-102105462-B | Amidophenoxyindazoles useful as inhibitors of C-MET | LILLY CO ELI | 2014-07-23 | — | — | CN | disclosed |
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2310382-B1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | LILLY CO ELI (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2310382-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | Eli Lilly & Company (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010011538-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| EP-0366614-B1 | PHARMACEUTICALLY ACTIVE DITHIOKETENE DERIVATIVES | YUHAN CORPORATION, LTD. (KR) | 1993-09-01 | — | — | EP | disclosed |
| US-5103013-A | For treating liver disorders | YUHAN CORPORATION, LTD. (KR) | 1992-04-07 | — | — | US | disclosed |
| EP-0366614-A2 | Pharmaceutically active dithioketene derivatives | YUHAN CORPORATION, LTD. (KR) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | ALDH1A1 557/4885MAPT 4577/4885KDM4E 4069/4885 |
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | ALDH1A1 4282/4885MAPT 2493/4885KDM4E 2816/4885 |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | MET, MYCBP, MYC | ALDH1A1 1450/4885MAPT 4502/4885KDM4E 1545/4885 |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, PLK2, MAP4K2 | ALDH1A1 4282/4885MAPT 2493/4885KDM4E 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.